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Abstract: Myasthenia gravis is an autoimmune neuromuscular disorder. There are several 
treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term 
immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, 
cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting 
short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term 
immunomodulation (thymectomy). This review explores in detail these different treatment 
options. Potential future treatments are also discussed.
Keywords: acetylcholinesterase inhibition, immunosuppression, immunomodulation, 
thymectomy
Introduction
Myasthenia gravis (MG) is a neuromuscular disorder characterized by a clinical 
course of fluctuating, painless muscle weakness. Typically it begins in the extraocular 
muscles and remains purely ocular in 15% of patients. MG generalizes by   descending to 
involve the bulbar muscles, and subsequently the neck, proximal limb, and   sometimes 
  respiratory muscles. Even with modern treatments, at least 20% of patients experience 
a myasthenic crisis which requires intubation and mechanical ventilation, usually 
within the first 2 years of the diagnosis.
MG is an autoimmune disorder usually caused by antibodies to postsynaptic 
proteins, mainly nicotinic acetylcholine receptor (AChR) and muscle-specific kinase 
(MuSK), but there are other as yet undiscovered antigens. These   antibodies reduce 
the number of functional AChRs and thus impair neuromuscular transmission. 
The prevalence of MG has increased from around 5 per million population between 
1915 and 19341 to about 200 per million population now,2 in part due to improved 
detection of the antibodies to the postsynaptic proteins. The estimated annual 
incidence of MG is between 1 in 10,000 to 1 in 50,000 of the population,3 but 
the clinical recognition of this rare disease remains difficult with many patients 
going undiagnosed for many months from symptom onset, and the diagnosis only 
  correctly made after several physician consultations. In the past 70 years, treatment 
advances have reduced the mortality of MG from 70% between 1915 and 19341 
to 5% or less now.4
In this review an overview will be given of the mechanism, evidence, indication, 
and relevant adverse effect profile of the different treatment options in generalized 
MG. Several potential future therapies will also be discussed.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Symptomatic treatment
Acetylcholinesterase inhibitors
In MG, the first-line option is symptomatic treatment with 
acetylcholinesterase inhibitors. Pyridostigmine bromide is 
the most commonly used drug. Other acetylcholinesterase 
inhibitors such as neostigmine are rarely used because of 
their poorer pharmacodynamic profiles and tolerability. 
In an observational study of 14 MG patients comparing 
pyridostigmine with neostigmine, it was concluded that 
over 1 year, pyridostigmine was more effective with less 
adverse events.5 Similar conclusions were reached in another 
observational study of 69 patients which compared the use 
of pyridostigmine with neostigmine.6 There is no large 
randomized controlled trial of acetylcholinesterase inhibitors 
in MG, but the clear response of this drug in observational 
studies would make depriving patients in the placebo arm of 
a randomized controlled trial unethical and unjustifiable.7
Pyridostigmine is most effective early in the course of MG 
and over time increasing tolerance to the drug develops which 
may necessitate dose escalation. Most MG patients do not 
achieve adequate response with acetylcholinesterase inhibitor 
treatment and will require further immunosuppression. It is also 
noteworthy that some MuSK antibody-positive patients may 
show nonresponsiveness to acetylcholinesterase inhibitors. In 
one study, 71% of MuSK antibody positive patients failed to 
respond to acetylcholinesterase inhibitors, compared to 18% 
respectively of AChR antibody positive and seronegative 
patients.8 Pyridostigmine is generally well tolerated. Adverse 
events include muscarinic side effects such as nausea, 
vomiting, abdominal cramping, diarrhea, diaphoresis, increased 
lacrimation, excessive respiratory secretions, bradycardia, and 
atrioventricular block. Antimuscarinics such as propantheline 
bromide provide effective symptomatic relief against the 
abdominal adverse events induced by pyridostigmine. 
Pyridostigmine may also cause nicotinic adverse events such 
as muscle cramps and fasciculations, but these rarely require a 
change in the dose of the drug. High doses of pyridostigmine 
may desensitize AChRs and induce weakness resulting in a 
cholinergic crisis. If there is such a concern, cholinesterase 
inhibitors need to be temporarily withdrawn and the patient 
carefully monitored for improvement.
Short-term immunosuppression
Corticosteroids
Corticosteroids are thought to act on the immune system 
by inhibiting the activation of T-cells and impairing the 
function of cells of the monocyte/macrophage lineage. 
Adrenocorticotrophic hormone (ACTH) was first described to 
have a beneficial effect in MG in 1935.9 ‘Good improvement’ 
was reported in a study of 100 patients with severe refractory 
MG given ACTH.10 In four large retrospective studies of 
generalized MG using various doses of corticosteroids 
and with different follow-up durations, 74% of a total of 
422 patients achieved good overall improvement of muscle 
strength or remission.11–14 A prospective study of 600 MG 
patients (151 generalized, 449 pure ocular) treated with 
moderate doses of corticosteroids followed by low-dose 
maintenance showed an overall improvement in 95% of 
cases, but no clear breakdown between the generalized and 
ocular cases were given.15
A randomized double-blind trial of prednisolone versus 
placebo in 13 patients with generalized MG showed no 
significant improvement of muscle strength at 6 months.16 
Another randomized double-blind trial of intravenous 
methylprednisolone versus placebo in 19 patients with 
generalized MG showed a significant short-term benefit 
from corticosteroids 2 weeks after treatment.17 An open-
label randomized trial comparing high-dose intravenous 
methylprednisolone and low-dose oral prednisolone in 
39 patients with juvenile MG (eight generalized and 
31 ocular) did not report any significant difference in 
improvement between the two groups, although the exact 
time of measurement and breakdown between the generalized 
and ocular cases were unclear from the paper.18
Corticosteroids are useful as short-term immunosup-
pressants in MG. Oral prednisolone is the most commonly 
used first-line drug. Corticosteroids are usually used as an 
interim measure while titrating up the doses of other immu-
nosuppressants and waiting for those immunosuppressants 
to take full effect. A temporary worsening of MG known 
as a ‘steroid dip’ may occur if corticosteroids are started 
at a high dose. This steroid dip usually occurs 4 to 10 days 
after starting treatment and may precipitate a MG crisis. To 
overcome this problem, treatment should be started at a low 
dose on alternate days19 and gradually titrated upwards.20 
In critically ill patients, high-dose daily corticosteroids 
can be started and additional short-term treatments such as 
intravenous immunoglobulin or plasma exchange can be 
used to overcome any temporary worsening.21 The potential 
adverse events from prolonged corticosteroid use necessitates 
a slow dose reduction to the minimum effective dose given 
on alternate days,20 but there is no clear evidence on the best 
time to reduce corticosteroids, how quickly or safely to do so, 
or how long patients should be kept on corticosteroids.21
Long-term corticosteroid use is associated with many 
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diabetes, osteoporosis, infections, psychiatric disorders, 
insomnia, and elevations in white blood cell count. Calcium, 
vitamin D and bisphosphonate supplement should be started 
concurrently with corticosteroids to protect against osteo-
porosis. In some patients, corticosteroid-induced myopathy 
needs to be differentiated from myasthenic weakness.
Long-term immunosuppression
Azathioprine
Azathioprine acts through its metabolite 6-mercaptopurine 
as a purine antagonist by inhibiting DNA synthesis and 
cell proliferation. There are several observational studies 
of azathioprine in MG. In a series of patients previously 
unresponsive to ACTH or glucocorticoids, 78% of 26 patients 
improved on azathioprine.22 In another study, 91% of 
78 patients improved when treated with azathioprine, given 
alone or in combination with corticosteroids, thymectomy or 
both.23 Another study showed 83% of 18 patients improved 
with azathioprine treatment alone for more than 6 months.24 
In a further study, all 41 MG patients followed for more than 
3 years improved when azathioprine was used either alone 
or in combination with prednisolone.25 In another study, 
75% of 32 patients treated with azathioprine monotherapy 
improved compared with 70% of 57 patients treated with a 
combination of azathioprine and corticosteroids.26 The use 
of early ‘high-dose’ immunosuppression with azathioprine 
and prednisolone resulted in 50% of MG patients achieving 
remission after 2 years, compared with a remission rate of 
only 16% in those on a ‘low-dose’ regimen.27
A randomized unblinded trial of azathioprine plus initial 
prednisolone versus prednisolone alone in 41 patients with 
generalized MG showed less clinical deterioration within the 
first 60 months (the primary endpoint) in the azathioprine 
group compared to the prednisolone monotherapy group, 
although no differences in muscle strength measurements 
were seen between the two groups.28 A further randomized 
double-blind trial of azathioprine plus prednisolone versus 
prednisolone plus placebo in 34 patients with generalized MG 
reported no significant differences between the two treatment 
groups with regard to objective or subjective muscle strength 
measurements.29 In the same study, the median prednisolone 
dose did not differ significantly between the two treat-
ment groups at 12 months, but was significantly reduced at 
36 months in the azathioprine plus prednisolone group com-
pared with the prednisolone plus placebo group, suggesting 
that azathioprine had a corticosteroid-sparing effect.29
In many countries, azathioprine is the first choice long-
term immunosuppressant drug which is started together with 
corticosteroids to allow tapering of the latter to the lowest 
possible dose. Common adverse events of azathioprine are 
hepatotoxicity, nausea, vomiting, rash, cytopenia, and pan-
creatitis. Malignancy, primarily lymphoma, is a potential 
long-term complication but the absolute risk is difficult to 
ascertain because it is difficult to differentiate the effects 
of the drug from age-related increases in the background 
incidence of cancer. Patients with deficiency of thiopurine 
S-methyltransferase may develop severe bone marrow-
related toxicity. Red cell thiopurine S-methyltransferase 
activity can be measured to identify at risk patients prior to 
starting treatment.
Cyclosporine
The effect of cyclosporine is mediated by calcineurin inhibi-
tion of T-cell interleukin-2 production. There are three uncon-
trolled trials of cyclosporine in patients with severe MG. In 
one trial, where patients recruited were unresponsive either to 
acethylcholinesterase inhibitors alone or to the combination 
of thymectomy plus corticosteroids or azathioprine, 80% of 
ten patients showed marked improvement after 12 months 
of treatment.30 In another trial of patients who had failed to 
respond to thymectomy, corticosteroids, azathioprine, or all 
three, 78% of nine patients showed marked improvement 
after a mean of 2 years’ treatment.31 In a third trial of patients 
who had not responded to thymectomy, corticosteroids and 
azathioprine, 85% of 52 patients showed marked improve-
ment after an average follow-up duration of 30 months’ 
treatment.32
A randomized double-blind trial of cyclosporine mono-
therapy versus placebo in 20 patients with generalized MG 
reported significantly greater increases in muscle strength in 
the cyclosporine group compared with the placebo group both 
at 6 and 12 months.33 Another randomized double-blind trial 
of cyclosporine plus prednisolone versus prednisolone plus 
placebo in 39 patients with generalized MG demonstrated 
that at 6 months, the cyclosporine group had a significantly 
greater increase in muscle strength than the placebo group.34 
Rather surprisingly, there was no significant difference in the 
percentage change of corticosteroid dose between the two 
groups at the end of 6 months;34 if cyclosporine is effective, it 
might be expected to have a corticosteroid-sparing effect.
Although cyclosporine has been shown to be clinically 
effective in MG, its use is limited by the potentially serious 
adverse events associated with this drug such as nephrotoxic-
ity, hypertension, and malignancy. Other common adverse 
events include flu-like symptoms, gingival hyperplasia, 
hypertrichosis, myalgia, and tremor.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Cyclophosphamide
Cyclophosphamide is a DNA-alkylating drug and nonspecific 
cell-cycle inhibitor. One study reported stable remissions in 
42 patients who were given cyclophosphamide for 2 to 37 months. 
Of these patients, 33 received concomitant corticosteroid 
treatment and five underwent thymectomy.35 A randomized 
double-blind trial of intravenous pulsed cyclophosphamide 
plus prednisolone versus prednisolone plus placebo in 
23 patients with severe generalized MG, demonstrated that 
cyclophosphamide significantly improved muscle strength 
at 12 months, but not at 6 months. The cyclophosphamide 
group also had significantly lower corticosteroid doses at 6 and 
12 months than at the start of the trial.36
Although there is evidence of clinical efficacy of cyclo-
phosphamide in MG, the use of the drug is restricted by its 
relatively high risk of severe adverse events such as bladder 
toxicity, bone marrow suppression, opportunistic infections, 
infertility, and malignancy. Other common adverse events 
associated with cyclophosphamide include nausea, vomiting, 
alopecia, abdominal pain, and diarrhea.
Methotrexate
Methotrexate is a folate antagonist that inhibits de novo 
synthesis of purines and pyrimidines. There are no good 
quality published studies of methotrexate in MG. However, 
methotrexate is still often used as second-line treatment 
in patients who do not tolerate or are unresponsive to 
azathioprine for several reasons: (a) data extrapolated 
from other autoimmune disorders suggest that it should be 
effective in MG,20 (b) expert panel guidelines support its use 
as second-line treatment in MG,20 and (c) many physicians 
have extensive personal experience of successfully using it 
in MG.21 A clinical trial to assess the efficacy of methotrexate 
in MG is underway.
Adverse events associated with methotrexate are usually 
mild such as alopecia, mucositis, gastrointestinal intolerance, 
and mild elevation of liver enzymes. Nevertheless, severe 
adverse events including hepatotoxicity, hematopoietic 
suppression, and pneumonitis may sometimes occur.
Mycophenolate mofetil
Mycophenolate mofetil, when converted to its active 
metabolite mycophenolic acid, inhibits T-cell proliferation 
by blocking purine synthesis. Several open-label trials of 
mycophenolate mofetil in MG have been published. In 
one trial, 68% of 22 patients who were either previously 
unresponsive to azathioprine, on combination therapy with 
corticosteroids or on mycophenolate mofetil monotherapy, 
treated for between 2 and 18 months demonstrated marked 
improvement.37 In another trial, 67% of twelve patients who had 
not responded to corticosteroids, azathioprine, cyclosporine, 
or thymectomy showed marked improvement after 6 months of 
treatment.38 In a further trial, 59% of 32 patients who had been 
unresponsive to corticosteroids, azathioprine, cyclosporine, 
methotrexate, or thymectomy showed marked improvement 
after an average of 11 months’ treatment.39 A retrospective 
analysis of mycophenolate mofetil in 85 MG patients, 48 of 
whom had undergone thymectomy and 66 of whom were 
on various combinations of corticosteroids, azathioprine, 
cyclosporine, and methotrexate, showed an improvement 
in 73% of patients.40 Another retrospective study of MG 
patients examined the effect of mycophenolate mofetil either 
as monotherapy or in combination with corticosteroids. In 
the monotherapy group, approximately 75% of 36 patients 
achieved a desirable outcome after 25 months of treatment, 
compared with approximately 16% when mycophenolate 
mofetil was initially started. In the mycophenolate mofetil 
plus corticosteroids group, approximately 75% of 66 patients 
achieved a desirable outcome after 24 months of treatment, 
compared with approximately 21% when mycophenolate 
mofetil was initially started.41
A randomized, double-blind trial of mycophenolate 
mofetil plus corticosteroids versus corticosteroids plus 
placebo of 176 MG patients for 36 weeks did not show 
efficacy for mycophenolate mofetil.42 Similarly, a second 
randomized double-blind trial of mycophenolate mofetil 
plus corticosteroids versus corticosteroids plus placebo of 
80 MG patients for 12 weeks failed to demonstrate efficacy 
for mycophenolate mofetil.43
The results of the two randomized controlled trials of 
mycophenolate mofetil were considered limited by their 
relatively short duration and greater than predicted benefit 
from the prednisolone doses used in the placebo arms of 
the studies.44,45 Since the drug is normally well tolerated 
with a relatively good adverse effect profile, it can be 
considered as third-line treatment in MG. The adverse 
events of mycophenolate mofetil are usually mild such as 
headache, nausea, and diarrhea, but more serious adverse 
events including infections, hematopoietic suppression, 
and hepatotoxicity can occasionally occur. Progressive 
multifocal leukoencephalopathy has been associated with 
mycophenolate mofetil treatment.
Rituximab
Rituximab is a chimeric monoclonal antibody against the 
B-cell surface marker CD20. In one series, six patients with Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
317
Treatments in myasthenia gravis
refractory MG (four MuSK antibody positive, two AChR 
antibody positive) were treated with rituximab, resulting in a 
decreased need for immunosuppressant treatment, improved 
clinical function or both in all patients.46 In another series, 
five patients with generalized MG resistant to conventional 
immunosuppression were treated with rituximab, with good 
clinical improvement reported in all.47 In a retrospective 
study of ten patients with generalized MG (three MuSK 
antibody positive, seven AChR antibody positive) refractory 
to conventional immunosuppressant treatment, rituximab 
resulted in 60% of patients (including all the MuSK antibody 
positive cases) improving clinically or being able to decrease 
immunosuppressant treatment.48 Another retrospective study 
of low-dose rituximab in refractory MG reported clinical 
improvement in 79% of the 14 patients (three MuSK anti-
body positive, eleven AChR antibody positive), including all 
MuSK antibody positive cases.49
There is preliminary evidence that rituximab is beneficial 
in MG, but it should only be used in severe refractory 
cases unresponsive to other treatments. Ongoing trials are 
evaluating its use. The current prohibitive cost of this drug 
is a major disadvantage. Common infusion-related adverse 
events associated with rituximab are fever, chills, nausea, 
vomiting, flushing, and bronchospasm. Other more severe 
adverse events include neutropenia, infections, and the risk 
of progressive multifocal leukoencephalopathy.
Tacrolimus
Tacrolimus inhibits T-cell and interleukin-2 production 
via the calcineurin-mediated pathway. In a 16-week, open-
label trial of 19 patients with generalized MG treated with 
low-dose tacrolimus, all of whom had previously undergone 
thymectomy and all but one of whom were on corticosteroid 
treatment, 37% showed clinical improvement at the end 
of the study.50 Furthermore, 67% of twelve patients from 
the previous study that continued tacrolimus for up to 2 
years showed clinical improvement.51 In another open trial 
of low-dose tacrolimus in thymectomized and corticosteroid-
dependent patients, 71% of the 17 patients treated improved 
clinically.52 In a further open-label study of tacrolimus in 
severe MG, where all patients were on prednisolone and 
cyclosporine, and had undergone thymectomy, 87% of the 
79 patients in the trial achieved pharmacological remission 
after a mean follow-up of 2.5 years.53 Another study examined 
the use of low-dose tacrolimus in 212 MG patients. These 
patients were either thymectomized, cyclosporine- and 
prednisolone-dependent patients, or thymectomized patients 
who started tacrolimus early postoperatively, or patients 
over 60 years old with nonthymomatous generalized MG 
or in whom thymectomy was contraindicated. This study, 
with a mean follow-up of 49.3 months, showed that muscle 
strength increased 23% after 1 month of treatment and 29% 
at the end of the study.54 A further published study of ten 
corticosteroid-dependent generalized MG patients treated 
with low-dose tacrolimus for a mean of 3.1 years reported 
that 50% of patients improved clinically at the end of the 
study.55 However, another study reported no significant 
clinical improvement in nine corticosteroid-dependent 
generalized MG patients treated with low-dose tacrolimus 
for 5 years.56 In another study, 86% of 47 generalized MG 
patients on low-dose tacrolimus over 24 weeks showed 
clinical improvement.57
One randomized unblinded nonplacebo controlled trial 
of tacrolimus plus corticosteroids with or without plasma 
exchange versus no tacrolimus plus corticosteroids with or 
without plasma exchange in 34 generalized MG patients 
showed that tacrolimus reduced the need for other immuno-
therapy such as plasma exchange and corticosteroids.58
Tacrolimus appears to be relatively safe at doses used in 
MG and can be considered as third-line treatment. Common 
adverse events include mild elevation of serum creatinine, 
hypertension, headache, hyperglycemia, tremor, parasthesia, 
decreased lymphocyte counts, and raised neutrophil counts. 
Tacrolimus may increase the risk of malignancy.
Rapid short-term 
immunomodulation
intravenous immunoglobulin
The mode of action of intravenous immunoglobulin in MG 
is incompletely understood, but key mechanisms include 
interference of signalling via Fc receptors, neutralization of 
activated complement, suppression of idiotypic antibodies, 
and modulation of proinflammatory cytokines. Intravenous 
immunoglobulin was first used in the 1980s in MG.59,60 Two 
reviews which collated results from previously published 
uncontrolled studies showed that intravenous immunoglobulin 
improved MG in more than 70% of cases.61,62 Two open 
studies of a total of 21 patients with severe generalized MG 
showed improvement with intravenous immunoglobulin in 
all patients.63,64 Intravenous immunoglobulin has been shown 
to have comparable effectiveness to plasma exchange in 
preoperative thymectomy preparation of MG patients.65,66
Five randomized controlled trials comparing intravenous 
immunoglobulin with placebo or other treatments in MG 
have been carried out. Two trials compared intravenous 
immunoglobulin to placebo. One trial of 15 patients Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with mild-to-moderate generalized MG showed no 
significant difference between the two groups at 6 weeks. 
In the same study, the clinical efficacy of intravenous 
immunoglobulin was similar whether 1.2 g/kg or 2 g/kg 
of intravenous immunoglobulin was used.67 In the other 
trial of 51 patients with acute exacerbation of generalized 
MG, intravenous immunoglobulin significantly improved 
muscle strength only in the group of patients with severe 
disease.68 Two trials compared intravenous immunoglobulin 
to plasma exchange. In the first trial with 87 patients with 
acute exacerbation of generalized MG, no significant change 
in muscle strength between day 0 and day 15 was observed 
between the two treatment groups.69 The second trial with 
a crossover design of 12 patients with moderate-to-evere 
MG in a stable phase showed no significant difference 
between the two groups after 1 and 4 weeks of treatment.70 
The Cochrane group reported that an unpublished, 
randomized controlled trial of intravenous immunoglobulin 
versus oral methylprednisolone in 33 patients with acute 
exacerbation of generalized MG failed to demonstrate any 
significant difference between the two treatment arms.71 
Another randomized controlled trial comparing two doses 
of intravenous immunoglobulin in 173 patients with acute 
exacerbation of generalized MG did not demonstrate any 
significant difference in efficacy between the doses of 
1 g/kg and 2 g/kg.72
There is some evidence that intravenous immunoglobulin 
is efficacious in acute severe exacerbation of generalized MG, 
but the evidence is less clear in chronic cases.73 Intravenous 
immunoglobulin is typically used in acute exacerbation of 
MG or to optimize muscle strength before surgery. Common 
adverse events associated with intravenous immunoglobulin 
include headache, nausea, fever, and allergic reaction. In 
patients with IgA deficiency which may be present in 1 in 
1000 people, a severe anaphylactic reaction might occur. 
Volume overload is a risk in cardiomyopathy and solute-
induced renal failure may occur in patients with pre-existing 
renal impairment. High infusion rates may be associated with 
thrombotic complications such as myocardial infarction and 
stroke. However, the rate of adverse events from intravenous 
immunoglobulin appears to be less severe than those from 
plasma exchange.69,70
Plasma exchange
Plasma exchange is thought to work in MG by removing 
circulating antibodies, cytokines, immune complexes, and 
other inflammatory mediators. In MG, the concentration of 
AChR and MuSK antibodies has been shown to decrease 
with plasma exchange.74,75 Plasma exchange was first used 
in the 1970s in MG.76 Several relatively large open studies 
of 20 or more patients, most of whom were already on 
other immunosuppressive or immunomodulatory treatment, 
have shown benefit from plasma exchange. Of 166 patients 
with generalized MG from five studies, 78% reported 
improvement with plasma exchange.77–81 Three fairly large 
retrospective studies totaling 84 patients with generalized 
MG showed improvement in 96% of patients.82–84 Another 
retrospective study of plasma exchange versus intravenous 
immunoglobulin in myasthenic crisis, demonstrated that 
the ventilatory status at 2 weeks and functional outcome 
after 1 month was better in the plasma exchange group.85 
A nonrandomized trial comparing different plasma 
exchange protocols in generalized MG failed to show any 
significant difference in efficacy between the treatments.86 
Prethymectomy plasmapheresis improves outcome after 
thymectomy in MG.87,88
One randomized controlled trial of plasma exchange 
versus prednisolone monotherapy in 14 patients with general-
ized MG did not show any significant difference in muscle 
strength between the two treatment arms after 1 month.89 
Two further randomized controlled trials comparing daily 
and alternate day plasma exchange in generalized MG did 
not show any significant difference in efficacy between the 
treatments.90,91
Plasma exchange is commonly used in acute severe 
exacerbation of MG to achieve temporary improvement 
or as a method of optimizing MG control before surgery. 
The choice between plasma exchange and intravenous 
immunoglobulin is often based on the physician’s opinion 
of the ability of a patient to tolerate each treatment. Since 
intravenous immunoglobulin is easier to administer, and 
associated with fewer adverse events than plasma exchange, 
and the efficacy of the two treatments is similar, the former 
is usually preferred to the latter.73 Most adverse events 
associated with plasma exchange are due to problems with 
vascular access such as infection, thrombosis, pneumothorax, 
and air embolism. Excessive fluid volume shift can result in 
hypotension or fluid overload and congestive cardiac failure. 
Citrate infused for anticoagulation may cause disturbances 
in acid–base homeostasis and hypocalcemia.
Long-term immunomodulation
Thymectomy
The mechanism by which thymectomy potentially benefits 
non-thymomatous patients with generalized MG is 
incompletely understood, but may involve disrupting B-cells Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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producing AChR antibodies. Although thymectomy has been 
the mainstay of treatment for non-thymomatous MG since 
the middle of the last centuary, a rigorous, evidence-based 
evaluation concluded that it only ‘might’ improve the chance 
of remission.92 An ongoing study is examining whether the 
addition of thymectomy to prednisolone monotherapy in 
AChR antibody positive patients leads to an overall reduction 
in the dose of prednisolone over 3 years.
Most retrospective studies indicate a better response 
to thymectomy when it is performed early in the disease 
course of generalized MG; thus the procedure is usually 
recommended within the first 3 years of diagnosis.93,94 There 
is no consensus on the age of non-thymomatous patients who 
should undergo thymectomy, but most experts restrict the 
procedure to patients under the age of 60–65 years because 
older patients usually have an atrophic thymus.93,94 Numerous 
approaches to thymus removal have been advocated, but the 
procedure that allows the greatest removal of thymic tissue 
would be expected to be the preferred option. Thymectomy 
is not recommended in MuSK antibody positive patients 
because retrospective analyses indicate a lack of typical 
thymus pathology in these patients.95 Whether a small 
proportion of seronegative MG patients do occasionally 
benefit from thymectomy remains controversial.
Thymectomy is always indicated in patients with thy-
moma to resect the neoplasm and treat the MG which occurs 
in about 10% of cases. Tumor removal in these cases does not 
always lead to remission and, indeed, the disease course in 
thymomatous patients is commonly more severe than in non-
thymomatous patients. Local irradiation and chemotherapy 
may be needed in certain more aggressive thymoma cases. 
Long-term monitoring for recurrence with computed tomog-
raphy or magnetic resonance imaging may be needed.
Emerging treatments
A number of potentially useful treatments show promise in 
animal models96 and theoretically.97
Animal models, such as the experimental autoimmune MG 
(EAMG) model which can be induced in different species, 
have been used to investigate several therapeutic possibilities. 
The most widely used models nowadays are rodents, and 
active immunization is with AChR from Torpedo electric 
organ which is a rich source of the receptor. In rats, both the 
acute and chronic phases of MG are present, as in humans, 
although the thymus is not involved.98 EAMG in mice is 
harder to induce, but mouse models have the advantage of the 
availability of mouse-specific reagents and knock-out strains 
which allow analyses which cannot be carried out in rats.
Different derivatives of AChR have been tested as potential 
therapeutic agents in EAMG. The first successful antigen-
specific immunomodulation of EAMG was performed in 
1978 with an intradermal injection of a chemically modified 
Torpedo AChR, where the denatured AChR derivative both 
prevented the induction of EAMG and suppressed the 
ongoing disease in rabbits.99 Native Torpedo AChR has 
also been shown to modulate EAMG,100–102 but the highly 
immunogenic nature of this native AChR103,104 has hampered 
its therapeutic application.
Advances in cloning and genetic engineering have led to 
the discovery that a certain region of the AChR molecule, 
termed the main immunogenic region, is the target of a large 
portion of the antibodies to AChR.105 Recombinant allogenic 
or syngeneic fragments to the appropriate regions of AChR 
have been shown to suppress acute and chronic manifesta-
tions of rat EAMG.106–109 It is thought that this approach 
suppresses autoimmune MG by inducing tolerance toward 
the self-autoantigen, rather than the directly neutralizing 
antibodies reacting with the autoantigen.
The use of synthetic peptides against immunodominant 
T- and B-cell epitopes within the AChR molecule is another 
potentially useful approach in MG. Several studies using 
such peptides have been associated with the amelioration 
of or protection from EAMG in rodent models.110–113 The 
autoimmune response in MG is polyclonal, thus peptides 
which represent only one or two dominant epitopes are 
unlikely to be effective. However, the use of peptide mixtures 
has been shown to be ineffective in rats with EAMG, possibly 
due to their inability to meet conformation requirements even 
when they are relatively long.114
Several approaches to influence key players in the 
immune process such as regulatory T-cells,115 dendritic 
cells,116 cytokines,117 costimulatory molecules,118 and comple-
ment pathways119 have also been shown to ameliorate or 
prevent EAMG.
Several techniques have been devised as alternatives to 
plasma exchange. These include immunoadsorption of anti-
AChR antibodies using gels or columns.120–122   However, the 
nonspecificity of these approaches leads to the indiscrimi-
nate removal of all, or most, immunoglobulins, including 
potentially useful antibodies. More antigen-specific immu-
noadsorbent approaches have being explored,123–125 with 
mixed results.
Conclusion
There remain major gaps in our knowledge of the treat-
ments used in generalized MG. Much of the evidence that Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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we use in determining the choice of treatment derives from 
  clinical experience, observational studies, and expert opinion. 
  Treatment regimens vary among different physicians, even 
from the same country, because many decisions are made 
primarily on the experience and familiarity of the treating 
physician to a particular regime. Furthermore, organizing ran-
domized controlled trials in MG is fraught with difficulties, 
not least that the rarity of the condition makes recruitment 
into trials a major obstacle. In addition, the phenotypical 
variability between AChR antibody positive, MuSK antibody 
positive and seronegative patients, and the fluctuating nature 
of MG are confounding factors in evaluating response to 
treatments. There is also a need to comparatively evaluate the 
effectiveness of current and emerging treatments in MG.
Various studies in experimental models of MG aim to 
develop novel and improved treatments that would have 
less adverse events than currently used treatments. Many 
promising ways to modulate the immune system in EAMG 
have been examined, but not all of these would necessarily 
be successful in human patients. It is worth noting that a 
multifaceted approach to the management of MG, with both 
antigen-specific immunotherapy and the direct modulation 
of key immunological factors involved in the autoimmune 
process, is likely to yield better treatments to improve the 
management of MG.
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